HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models.

AbstractPURPOSE:
The aim of the study was to demonstrate the activity of etirinotecan pegol, a polymer conjugate of irinotecan, in multiple human tumor models and to establish both the pharmacokinetic/pharmacodynamics (PK/PD) relationship and clinical relevance of the findings.
EXPERIMENTAL DESIGN:
Anti-tumor activity was evaluated in mouse models of human lung, colorectal, breast, ovarian, and gastric cancers. Etirinotecan pegol was administered intravenously (once or every 3-7 days) to animals with established tumors. Activity was assessed by tumor growth delay (TGD) and regression. Mice bearing established colorectal and lung tumors were treated with etirinotecan pegol or irinotecan, and serial blood and tumor samples were collected at planned times between 0 and 60 days post-treatment for quantitation of etirinotecan pegol and SN38. For PK analysis, analyte concentration-time data were fit with compartmental models; PK/PD analysis was based on an inhibitory E max response model.
RESULTS:
Etirinotecan pegol was active in all tumor models. TGD was sustained for 2-10 weeks after last dose, while conventional irinotecan resulted in little suppression of tumor growth. Etirinotecan pegol was eliminated very slowly from the tumor (t 1/2 = 17 days), achieving higher and more sustained tumor exposure when compared with conventional irinotecan. The increased tumor exposure following etirinotecan pegol correlated with strong and prolonged suppression of tumor growth. Sustained plasma exposure to active SN38 was consistently observed across nonclinical species (including mouse, rat, and dog) and translated to cancer patients.
CONCLUSIONS:
Etirinotecan pegol is the first long-acting topoisomerase 1 inhibitor that provides sustained exposure, which results in prolonged anti-tumor activity in a wide variety of cancer models.
AuthorsUte Hoch, Carl-Michael Staschen, Randall K Johnson, Michael A Eldon
JournalCancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 74 Issue 6 Pg. 1125-37 (Dec 2014) ISSN: 1432-0843 [Electronic] Germany
PMID25228368 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Heterocyclic Compounds with 4 or More Rings
  • Topoisomerase I Inhibitors
  • etirinotecan pegol
  • Polyethylene Glycols
  • irinotecan
  • Camptothecin
Topics
  • Animals
  • Antineoplastic Agents (administration & dosage, pharmacokinetics, pharmacology)
  • Camptothecin (analogs & derivatives, pharmacology)
  • Dogs
  • Female
  • Heterocyclic Compounds with 4 or More Rings (administration & dosage, pharmacokinetics, pharmacology)
  • Humans
  • Male
  • Mice
  • Mice, Nude
  • Mice, SCID
  • Neoplasms, Experimental (drug therapy, pathology)
  • Polyethylene Glycols (administration & dosage, pharmacokinetics, pharmacology)
  • Rats
  • Rats, Sprague-Dawley
  • Species Specificity
  • Topoisomerase I Inhibitors (administration & dosage, pharmacokinetics, pharmacology)
  • Treatment Outcome
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: